NCT06514768 JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.

This trial targets 20 participants in total. It began in 2024-06-20 with a primary completion date of 2026-06-30.

Brief Summary

Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of B-cell acute lymphoblastic leukemia (B-ALL)

Eligibility Criteria

Inclusion Criteria: 1. up to 75 years (Child, Adult) , either sex； 2. Bone marrow cell morphology examination showed the proportion of primitive and immature lymphocytes in the bone marrow is \>5%, or the bone marrow MRD analysis comfirmed as B-ALL. 3. Flow cytometry or histology confirmed positive expression of cluster of differentiation 19 (CD19); 4. According to the researcher's assessment, the expected survival period is greater than 3 months; 5. Eastern Cooperative Oncology Group (ECOG) physical condition score ≤ 3; 6. The patient has good liver, kidney, heart, and lung functions: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × upper limit of normal(ULN), which can be relaxed to ≤ 5 × ULN for patients with liver invasion; Total serum bilirubin \< 34 μ Mol/L; Creatinine clearance rate\>30 mL/min; Cardiac ejection fraction (EF) ≥ 40%, without pericardial effusion and significant arrhythmia; Indoor oxygen saturation (SpO2) ≥ 92%; 7. Peripheral blood lymphocyte absolute count: absolute lymphocyte count (ALC) ≥ 0.5E9/L, blood platelet (PLT) \> 30E9/L, Hb \> 80g/L, with a single venous access and no other contraindications for blood cell separation; 8. MRI examination showed no active malignant cells in the cerebrospinal fluid, no brain metastases, or no central nervous system leukemia; 9. Individuals with fertility must agree to the use of efficient contraceptive methods; 10. The subject or their legal guardian can understand and voluntarily sign a written informed consent form. Exclusion Criteria: 1. Pregnant or lactating women, as well as women with pregnancy plans within six months; 2. Virological tests of hepatitis B, hepatitis C, AIDS, syphilis and cytomegalovirus were positive; 3. Having a history of other tumors (excluding skin or cervical carcinoma in situ cured by root therapy and without evidence of disease activity); 4. Previously received treatment targeting CD19; 5. Received autologous hematopoietic stem cell transplantation within 6 weeks; 6. The presence of uncontrollable active bacterial or fungal infections; 7. Allergies to research related drugs or cellular components; 8. Active autoimmune diseases exist; 9. Patients with unstable or active ulcers or gastrointestinal bleeding currently present; 10. Individuals with mental or psychological disorders who cannot cooperate with treatment and efficacy evaluation; 11. Received other experimental drug treatments within the past 3 months; 12. Existence of grade II-IV acute graft versus-host disease (GVHD) or widespread chronic GVHD; 13. Researchers believe that other reasons are not suitable for clinical trial participants.

Contact & Investigator

Frequently Asked Questions

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.